ID
45956
Beschreibung
Principal Investigator: Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA MeSH: Carcinoma,Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000855 The purpose of the study was to compare gene expression profiles from a cohort of crizotinib-resistant ALK-rearranged lung tumors and a cohort of treatment-naive ALK-rearranged lung tumors. Expression profiles were generated by RNA-seq. In parallel, gene expression profiles were obtained from ALK-rearranged lung cancer cell lines in the presence or absence of the ALK inhibitor TAE684. Gene expression profiles were also obtained from ALK-rearranged cells ectopically expressing genes associated with ALK inhibitor resistance that were identified from a functional genetic study.
Link
Stichworte
Versionen (2)
- 15.03.24 15.03.24 - Dr. Christian Niklas
- 16.03.24 16.03.24 - Madita Rudolph
Rechteinhaber
Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA
Hochgeladen am
16. März 2024
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
dbGaP phs000855 Resistance studies in Lung Cancer
Sample ID, sample type [tumor], and analyte type of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID, sample ID, and sample use variable obtained from participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID and sext of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Sample ID, sample type [tumor], and analyte type of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
Ähnliche Modelle
Sample ID, sample type [tumor], and analyte type of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID, sample ID, and sample use variable obtained from participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID and sext of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Sample ID, sample type [tumor], and analyte type of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
C1299222 (UMLS CUI [1,2])
C2347026 (UMLS CUI [1,2])
C0475752 (UMLS CUI [1,3])
C0205307 (UMLS CUI [1,4])
C0449438 (UMLS CUI [1,5])